Medpace CEO August Troendle sells $1.59 million in stock

August J. Troendle, CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), divested a substantial portion of his personal stake in the company, selling approximately $1.59 million worth of common stock on September 25 and September 28, 2026. The shares were sold at prices ranging from $620.07 to $620.60 per share, with the total number of shares amounting to 1,564.

This move occurred during a defined time frame, as per a limit order Mr. Troendle placed. Currently, the stock price stands at $669.20, nearing its 52-week high of $684.52. Despite this significant sale, Troendle still holds a substantial stake in the company, with 386,892 shares directly owned and an additional 4.73 million shares indirectly held through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.

Recently, Medpace Holdings reported strong financials for the third quarter of 2026, surpassing market expectations with an adjusted profit of $4.84 per share. Revenue for the quarter reached $716 million, marking an 8.5% increase from the previous year. The company also achieved record-high net new business awards, which contributed to an expanded backlog.

Management has revised its revenue and profit guidance for the year, although 2027 guidance remains pending due to factors such as awards and cancellations. The company has noted strong demand in its oncology segment, despite a slight decrease in cardiometabolic demand, pointing to a positive business environment driven by high-quality request-for-proposal activity and expeditious customer decision-making.